Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine

Behavioural Pharmacology

Volumn 23, Issue 1, 2012, Pages 66-79

  Zhang, Chen ^a,b   Li, Ming ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

behavioral sensitization; conditioned avoidance response; haloperidol; olanzapine; phencyclidine; rat; time course of antipsychotic effect

Indexed keywords

HALOPERIDOL; OLANZAPINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR; BEHAVIOR CONTROL; CONDITIONING; CONTROLLED STUDY; EXPERIMENTAL ANIMAL; MALE; NEUROBIOLOGY; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84855669469     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32834ecac4     Document Type: Article

References (58)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235. (Pubitemid 37494076)
2. Agid O, Seeman P, Kapur S (2006). The 'delayed onset' of antipsychotic action: an idea whose time has come and gone. J Psychiatry Neurosci 31:93-100.
3. Amtage J, Schmidt WJ (2003). Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behav Pharmacol 14:563-567. (Pubitemid 38293517)
4. Anagnostaras SG, Robinson TE (1996). Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110:1397-1414. (Pubitemid 27009202)
5. Anagnostaras SG, Schallert T, Robinson TE (2002). Memory processes governing amphetamine-induced psychomotor sensitization. Neuropsycho- pharmacology 26:703-715. (Pubitemid 34455023)
6. Browman KE, Badiani A, Robinson TE (1998). Modulatory effect of environmental stimuli on the susceptibility to amphetamine sensitization: a dose-effect study in rats. J Pharmacol Exp Ther 287:1007-1014. (Pubitemid 29131614)
7. Buckland PR, D'Souza U, Maher NA, McGuffin P (1997). The effects of antipsychotic drugs on the mRNA levels of serotonin 5HT2A and 5HT2C receptors. Brain Res Mol Brain Res 48:45-52. (Pubitemid 27298127)
8. Emsley R, Rabinowitz J, Medori R (2006). Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 163:743-745. (Pubitemid 44464590)
9. Geyer MA, Ellenbroek B (2003). Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1071-1079. (Pubitemid 37464953)
10. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156:117-154. (Pubitemid 32702206)
11. Gleason SD, Shannon HE (1997). Blockade of phencyclidine-induced hyperlo-comotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 129:79-84. (Pubitemid 27037454)
12. Glick ID, Shkedy Z, Schreiner A (2006). Differential early onset of therapeutic response with risperidone vs. conventional antipsychotics in patients with chronic schizophrenia. Int Clin Psychopharmacol 21:261-266. (Pubitemid 44162477)
13. Holland PC (1989). Transfer of negative occasion setting and conditioned inhibition across conditioned and unconditioned stimuli. J Exp Psychol Anim Behav Process 15:311-328.
14. Kapur S, Arenovich T, Agid O, Zipursky R, Lindborg S, Jones B (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162:939-946. (Pubitemid 40676207)
15. Kilts CD (2001). The changing roles and targets for animal models of schizophrenia. Biol Psychiatry 50:845-855. (Pubitemid 34020698)
16. Klein A, Schmidt WJ (2003). Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behav Pharmacol 14:49-53. (Pubitemid 36279025)
17. Konradi C, Heckers S (2001). Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 50:729-742. (Pubitemid 33086760)
18. Lanis A, Schmidt WJ (2001). NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent. Behav Pharmacol 12:143-149. (Pubitemid 32458126)
19. Leucht S, Busch R, Hamann J, Kissling W, Kane JM (2005). Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57:1543-1549. (Pubitemid 40805384)
20. Li M, Davidson P, Budin R, Kapur S, Fleming AS (2004a). Effects of typical and atypical antipsychotic drugs on maternal behavior in postpartum female rats. Schizophr Res 70:69-80. (Pubitemid 38916630)
21. Li M, Parkes J, Fletcher PJ, Kapur S (2004b). Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav 78:811-819. (Pubitemid 39037744)
22. Li M, Fletcher PJ, Kapur S (2007). Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272. (Pubitemid 46106933)
23. Li M, He W, Mead A (2009a). An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm. Behav Pharmacol 20:184-194.
24. Li M, He W, Mead A (2009b). Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pre-treated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol 20:84-98.
25. Li M, Sun T, Zhang C, Hu G (2010). Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning. Psychopharmacology (Berl) 212:45-57.
26. Li M, He E, Volf N (2011a). Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment. Pharmacol Biochem Behav 98:559-569.
27. Li M, Sun T, Mead A (2011b). Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT(2A/2C) receptors. J Neural Tr a n s m [Epub ahead of print].
28. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, et al. (2008). Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60: 358-403.
29. Maes JH, Vossen JM (1997). Conditional control by midazolam and amphetamine in a rapid appetitive discrimination procedure. Eur J Pharmacol 319:5-11. (Pubitemid 27051309)
30. Marcus MM, Nomikos GG, Malmerfelt A, Zachrisson O, Lindefors N, Svensson TH (1997). Effect of chronic antipsychotic drug treatment on preprosoma-tostatin and preprotachykinin A mRNA levels in the medial prefrontal cortex, the nucleus accumbens and the caudate putamen of the rat. Brain Res Mol Brain Res 45:275-282. (Pubitemid 27170704)
31. McCoy L, Cox C, Richfield EK (1996). Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. Eur J Pharmacol 318:41-45. (Pubitemid 27033202)
32. Mead A, Li M (2010). Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol 24:1045-1053.
33. Meltzer HY, Matsubara S, Lee JC (1989). The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 25:390-392. (Pubitemid 20260244)
34. Meltzer HY, Li Z, Kaneda Y, Ichikawa J (2003). Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172. (Pubitemid 37464960)
35. Nudmamud S, Reynolds GP (2001). Increased density of glutamate/N-methyl- D-aspartate receptors in superior temporal cortex in schizophrenia. Neurosci Lett 304:9-12. (Pubitemid 32373304)
36. Ohmori T, Abekawa T, Ito K, Koyama T (2000). Context determines the type of sensitized behaviour: a brief review and a hypothesis on the role of environment in behavioural sensitization. Behav Pharmacol 11:211-221. (Pubitemid 30449753)
37. Pierce RC, Kalivas PW (1997). A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev 25:192-216. (Pubitemid 27501800)
38. Poulos CX, Hinson R (1982). Pavlovian conditional tolerance to haloperidol catalepsy: evidence of dynamic adaptation in the dopaminergic system. Science 218:491-492.
39. Poulos CX, Hinson RE, Siegel S (1981). The role of Pavlovian processes in drug tolerance and dependence: implications for treatment. Addict Behav 6:205-211. (Pubitemid 12243142)
40. Raedler TJ, Schreiner A, Naber D, Wiedemann K (2007). Early onset of treatment effects with oral risperidone. BMC Psychiatry 7:4.
41. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res 396:157-198. (Pubitemid 16100809)
42. Robinson TE, Browman KE, Crombag HS, Badiani A (1998). Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22:347-354. (Pubitemid 28194391)
43. Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S (2007). 'Breakthrough' dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27:2979-2986. (Pubitemid 46438984)
44. Samaha AN, Reckless GE, Seeman P, Diwan M, Nobrega JN, Kapur S (2008). Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biol Psychiatry 64:145-152.
45. Schmitt A, Zink M, Muller B, May B, Herb A, Jatzko A, et al. (2003). Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 28:235-241. (Pubitemid 36207348)
46. Seeman P (2000). Antipsychotic drugs, dopamine D2 receptors and schizophrenia. In: Lidow MS, editor. Neurotransmitter receptors in actions of antipsychotic medications. Boca Raton, Florida: CRC Press LLC. pp. 43-63.
47. Siegel S (1978). Pavlovian conditioning analysis of morphine tolerance. NIDA Res Monogr 18:27-53.
48. Siegel S, Baptista MA, Kim JA, McDonald RV, Weise-Kelly L (2000). Pavlovian psychopharmacology: the associative basis of tolerance. Exp Clin Psycho-pharmacol 8:276-293.
49. Smith JB (1991). Situational specificity of tolerance to decreased operant responding by morphine and l-nantradol. Psychopharmacology (Berl) 103:115-120.
50. Sripada S, Gaytan O, Swann A, Dafny N (2001). The role of MK-801 in sensitization to stimulants. Brain Res Brain Res Rev 35:97-114. (Pubitemid 32411468)
51. Stewart J, Vezina P (1991). Extinction procedures abolish conditioned stimulus control but spare sensitized responding to amphetamine. Behav Pharmacol 2:65-71.
52. Sun T, Hu G, Li M (2009). Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602: 334-342.
53. Tarsy D, Baldessarini RJ (1974). Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacology 13: 927-940.
54. Tooney PA, Anderson WB, Lynch-Frame A, Chahl LA (2005). The effects of haloperidol treatment on the distribution of NK1 receptor immunoreactive neurons in guinea pig brain. Neurosci Lett 383:155-159. (Pubitemid 40779974)
55. Vezina P, Stewart J (1984). Conditioning and place-specific sensitization of increases in activity induced by morphine in the VTA. Pharmacol Biochem Behav 20:925-934. (Pubitemid 14089142)
56. Vezina P, Giovino AA, Wise RA, Stewart J (1989). Environment-specific cross-sensitization between the locomotor activating effects of morphine and amphetamine. Pharmacol Biochem Behav 32:581-584. (Pubitemid 19139020)
57. Weiner I, Feldon J (1994). The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action: comment on Dunn, Atwater and Kilts (Psychopharmacology 1993;112:315-323). Psychopharmacology (Berl) 116:379-381.
58. Wise RA, Bozarth MA (1987). A psychomotor stimulant theory of addiction. Psychol Rev 94:469-492.